Home>>Signaling Pathways>> DNA Damage/DNA Repair>> Checkpoint Kinase (Chk)>>PD 407824

PD 407824

Catalog No.GC18396

PD 407824 is an inhibitor of the checkpoint kinases Chk1 and WEE1 (IC50s = 47 and 97 nM, respectively).

Products are for research use only. Not for human use. We do not sell to patients.

PD 407824 Chemical Structure

Cas No.: 622864-54-4

Size Price Stock Qty
10mM 1 mL in DMSO
$89.00
In stock
1mg
$50.00
In stock
5mg
$124.00
In stock
10mg
$228.00
In stock
25mg
$436.00
In stock
50mg
$743.00
In stock
100mg
$1,287.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

PD 407824 is an inhibitor of the checkpoint kinases Chk1 and WEE1 (IC50s = 47 and 97 nM, respectively). It is selective for Chk1 and WEE1 over PKC (IC50 = 3.4 uM), Cdk4 (IC50 = 3.75 uM), as well as c-Src and the PDGF and FGF receptors (IC50s = >50 uM for all), and other Cdks (IC50s = >50 uM). PD 407824 sensitizes SK-OV-3 and OVCAR-3 ovarian cancer cells, as well as cisplatin-resistant A2780cis cells, to cisplatin when used at a concentration of 0.5 uM. It also sensitizes C2C12 myoblasts to bone morphogenic protein 4 (BMP4) and, when used in combination with BMP4, inhibits myotube formation and induces myoblasts to differentiate into mature osteoblasts. PD 407824, in combination with BMP4, induces human embryonic stem cells to differentiate into cells with mesoderm or cytotrophoblast stem cell lineages.

Reviews

Review for PD 407824

Average Rating: 5 ★★★★★ (Based on Reviews and 26 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for PD 407824

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.